We are live on ! Find out more
A

Abingworth Portfolio holdings

AUM $307M
1-Year Est. Return 93.47%
This Fund
S&P 500
This Quarter Est. Return
+19.1%
1 Year Est. Return
+93.47%
3 Year Est. Return
+184.38%
5 Year Est. Return
+342.7%
10 Year Est. Return
–
AUM
$104M
AUM Growth
+$8.84M
Cap. Flow
-$2.7M
Cap. Flow %
-2.59%
Top 10 Hldgs %
85.86%
Holding
22
New
2
Increased
1
Reduced
1
Closed
2

Top Buys

Rank Stock Value
1
NOVN
Novan, Inc. Common Stock
NOVN
+$4.18M
2
OCGN icon
Ocugen
OCGN
+$461K
3
ANTH
Anthera Pharmaceuticals, Inc.
ANTH
+$233K

Top Sells

Rank Stock Value
1
TBRA
Tobira Therapeutics, Inc. Common Stock
TBRA
+$7.38M
2
AUPH icon
Aurinia Pharmaceuticals
AUPH
+$200K
3
EPRS
EPIRUS BIOPHARMACEUTICALS INC COM
EPRS
+$4K

Sector Composition

Rank Sector Weight
1 Healthcare 87.9%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SIEN
1
DELISTED
Sientra, Inc.
SIEN
$19.8M 18.95%
219,901
– –
TARA icon
2
Protara Therapeutics
TARA
$220M
$18.4M 17.62%
50,447
– –
PRTK
3
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
$16.9M 16.22%
1,301,413
– –
CEMP
4
DELISTED
Cempra, Inc.
CEMP
$9.29M 8.9%
383,935
– –
CHMA
5
DELISTED
Chiasma, Inc. Common Stock
CHMA
$6.1M 5.84%
2,080,595
– –
DRNA
6
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$5.56M 5.33%
945,757
– –
NOVN
7
DELISTED
Novan, Inc. Common Stock
NOVN
$4.03M 3.86%
+20,000
New +$4.18M
INNL
8
DELISTED
Innocoll Holdings plc Ordinary Shares
INNL
$3.23M 3.09%
555,555
– –
EVAR
9
DELISTED
Lombard Medical, Inc.
EVAR
$3.2M 3.07%
3,473,452
– –
CBAY
10
DELISTED
Cymabay Therapeutics
CBAY
$3.1M 2.98%
1,600,000
– –
CLLS
11
Cellectis
CLLS
$277M
$2.41M 2.31%
100,000
– –
DERM
12
DELISTED
Dermira, Inc.
DERM
$2.37M 2.27%
70,000
– –
SENS icon
13
Senseonics Holdings Inc
SENS
$263M
$2M 1.92%
25,844
– –
ADAP
14
DELISTED
Adaptimmune Therapeutics
ADAP
$1.76M 1.69%
250,000
– –
ANTH
15
DELISTED
Anthera Pharmaceuticals, Inc.
ANTH
$1.53M 1.47%
64,005
+9,256
+17% +$233K
IMDZ
16
DELISTED
Immune Design Corp.
IMDZ
$1.49M 1.43%
197,300
– –
AUPH icon
17
Aurinia Pharmaceuticals
AUPH
$1.91B
$1.38M 1.32%
437,994
-74,042
-14% -$200K
RGLS
18
DELISTED
Regulus Therapeutics
RGLS
$1.08M 1.04%
2,728
– –
OCGN icon
19
Ocugen
OCGN
$416M
$543K 0.52%
+2,948
New +$461K
ACHV icon
20
Achieve Life Sciences
ACHV
$659M
$195K 0.19%
180
– –
TBRA
21
DELISTED
Tobira Therapeutics, Inc. Common Stock
TBRA
– –
-589,244
Closed -$7.38M
EPRS
22
DELISTED
EPIRUS BIOPHARMACEUTICALS INC COM
EPRS
– –
-7,896
Closed -$4K

Similar funds

AAM
Arabesque Asset Management London, United Kingdom $296M AUM 15.19% 1-Year Est. Return
EP
Equius Partners Novato, California $324M AUM 8.27% 1-Year Est. Return
LDFR
Lehman & Derafelo Financial Resources Media, Pennsylvania $337M AUM 8.16% 1-Year Est. Return
MPAM
Monarch Partners Asset Management Boston, Massachusetts $339M AUM 2.52% 1-Year Est. Return
MAG
Mass Ave Global New York $342M AUM 20.58% 1-Year Est. Return
CDIA
Capital Directions Investment Advisors Atlanta, Georgia $268M AUM 20.15% 1-Year Est. Return
GTCM
Gyon Technologies Capital Management Denville, New Jersey $267M AUM 11.62% 1-Year Est. Return
ACMV
August Capital Management VII Palo Alto, California $265M AUM 26.86% 1-Year Est. Return

Abingworth's Q3 2016 Portfolio in Review

As of Q3 2016, Abingworth held 22 positions worth $104M, up 9.3% from $95.5M the previous quarter. Its ten largest holdings account for 86% of the portfolio.

Abingworth's Q3 2016 filing shows 2 new, 1 increased, 1 reduced and 2 closed positions. Its largest new stake was Novan, Inc. Common Stock: 20,000 shares worth $4.03M. The largest sale was Tobira Therapeutics, Inc. Common Stock, an estimated $7.38M.

By sector, the portfolio is most concentrated in Healthcare at 88% of assets, down from 89% a quarter earlier.

  • Abingworth's largest Q3 2016 buy was Novan, Inc. Common Stock: 20,000 shares worth $4.03M.
  • Abingworth added most to Anthera Pharmaceuticals, Inc. in Q3 2016, an estimated $233K increase.
  • Abingworth's biggest Q3 2016 reduction was Aurinia Pharmaceuticals, cutting an estimated $200K.
  • Abingworth fully exited Tobira Therapeutics, Inc. Common Stock in Q3 2016, selling an estimated $7.38M.
  • Abingworth's ten largest holdings make up 86% of its $104M portfolio in Q3 2016.
  • Abingworth opened 2 new positions and closed 2 in Q3 2016.
  • Abingworth's portfolio value rose 9.3% quarter-over-quarter to $104M.

Based on Abingworth's 13F filing for Q3 2016, filed 14 Nov 2016.